Separate or defined areas to prevent contamination or mix-ups are deficient regarding the manufacturing and processing operations.
See every finding in this document View the regulator's official sourceBy Category
US FDA Contamination control findings
by this agency in this category 497 findings drawn from 404 published documents. The most recent cases are below; the full set is in search.
See all US FDA Contamination control findingsCompanies with the most findings
Recent findings
Separate or defined areas to prevent contamination or mix-ups are deficient regarding the manufacturing and processing operations.
View the regulator's official sourceSeparate or defined areas to prevent contamination or mix-ups are deficient regarding the manufacturing and processing operations.
See every finding in this document View the regulator's official sourceMicrobial contamination was present in the ISO 5 area.
See every finding in this document View the regulator's official sourceContamination was observed in your areas adjacent to production areas.
See every finding in this document View the regulator's official sourceHazardous drugs and Highly potent drugs were produced without providing adequate containment, segregation, and/or cleaning ofwork surfaces, utensils, and/or personnel to prevent cross-contamination.
See every finding in this document View the regulator's official sourceOther agencies
These findings are a record of the moment each document was published. Inspection findings are usually followed by the company's response and corrective action, but this page does not know how that turned out — do not read them as the current state; check the regulator's official announcements for the latest status. Counts are measured from public data as of 2026-10-20, and findings are extracted automatically from the regulator's published documents. “View official source” on each case links directly to that document.
